Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,471,017 shares of the biopharmaceutical company's stock after selling 580,550 shares during the quarter. Victory Capital Management Inc. owned approximately 0.20% of Gilead Sciences worth $276,877,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Annis Gardner Whiting Capital Advisors LLC raised its position in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Core Alternative Capital raised its position in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on GILD. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Oppenheimer lowered their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $111.38.

Gilead Sciences Trading Up 0.1%

Gilead Sciences stock traded up $0.08 during mid-day trading on Friday, hitting $108.88. The company's stock had a trading volume of 1,703,203 shares, compared to its average volume of 8,605,349. The firm has a market capitalization of $135.44 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 1 year low of $70.78 and a 1 year high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock's fifty day moving average is $108.58 and its two-hundred day moving average is $105.06.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.32) earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were given a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,000 shares of company stock valued at $7,844,775. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.